Seeing Light At End Of Pandemic Tunnel, Prestige Consumer Healthcare Raises Earnings Guidance
Executive Summary
Prestige Consumer Healthcare prepares to “lap the effects” of COVID-19 disruption on, estimating its fiscal year 2021 sales will reach $935m, ahead of earlier projections, and maintaining long-term organic growth targets of 2%-3%.
You may also be interested in...
Prestige Consumer’s ‘Nimble’ Marketing Helps Beat Fiscal 2021 Guidance
Less travel, closed schools and a slower cold/cough season during the pandemic required Prestige Consumer to invest strategically across its OTC healthcare portfolio in fiscal 2021. Dramamine motion sickness and Nix head lice treatments got less attention, while Monistat, Compound W and Clear Eyes received more.
US OTC Market In 2020: COVID-19 Impact Obvious In Medical Device As Well As Drug Sales Growth
Most notably among OTC drugs, hand sanitizer sales were up more than 600% to $1.46bn, while sales of consumer medical devices grew 15.6% to $14.8bn in 2020, according to CHPA report.
Prestige Consumer Expects 4% Sales Dip For Its FY2021 As COVID-19 Clouds Economic Forecast
North American sales for the consumer health segment in the quarter reached $216.6m core products on women’s health, analgesics, oral care and ear and eye care categories, partially offset by declines in cough and cold products as well as gastrointestinal products.